CG Oncology shares jump as cretostimogene cuts bladder cancer recurrence by 68%
CG Oncology (CGON) shares rose 14% after reporting that its immunotherapy, cretostimogene, reduced bladder cancer recurrence by 68% in a Phase III trial. The trial involved 367 patients and showed the treatment was well-tolerated. Median follow-up was 17 months.
How this was made

The 30-second read
Why it matters
Meeting the Phase III primary endpoint with a large recurrence-risk reduction and a clean safety profile is a material de-risking event that can shift valuation expectations and increase interest from partners and future trial planners.
Market read
Traders can reassess probability-weighted outcomes for cretostimogene and the broader NMIBC immunotherapy landscape based on this pivotal readout.
What to watch
Trial design details (open-label, surveillance comparator) and the need for confirmatory endpoints or subgroup consistency could temper how far the market extrapolates from the primary endpoint.
Background
Cretostimogene grenadenorepvec is an oncolytic immunotherapy being evaluated in NMIBC; PIVOT-006 is a Phase III trial in intermediate-risk and high-grade Ta disease.
Ticker impact
CG Oncology shares jumped after Phase III PIVOT-006 data showed cretostimogene reduced bladder cancer recurrence risk by 68% vs surveillance.
Likely upward pressure as traders price in improved clinical validation and potential path to approval, with volatility around follow-up details.
The article reports primary endpoint achievement with a large relative risk reduction and favorable safety (no grade 3+ treatment-related AEs), which is a direct, decision-relevant catalyst for a clinical-stage biotech.
Market effects
Strengthens sentiment for oncolytic immunotherapy and NMIBC pipeline assets, potentially lifting peer group risk appetite.
Limited direct regional spillover beyond US-listed biotech sentiment.
Moderate global relevance as bladder cancer immunotherapy efficacy data can influence international development and partnering expectations.
Counterpoint
A 17-month median follow-up may be insufficient to fully characterize durability and long-term recurrence-free survival, so the initial reaction could fade if longer follow-up disappoints.
Key entities
- companyCG Oncology
Dallas-based company developing cretostimogene grenadenorepvec; reported Phase III PIVOT-006 primary endpoint success.
- drugcretostimogene grenadenorepvec
Oncolytic immunotherapy evaluated as adjuvant therapy after tumor resection in NMIBC.
- clinical_trialPIVOT-006
Phase III randomized open-label trial in intermediate-risk and high-grade Ta NMIBC; primary endpoint met.


